Tumor cells present a mosaic of genetic mutations that can drive tumor development and progression. Mutations present only in tumor samples are called somatic mutations and can be exploited for immunotherapeutic interventions that utilize the patient’s own immune system to target and eliminate cancer cells. This mutational fingerprint is cancer-specific and allows for a clear distinction between normal and cancerous tissues. Thanks to this specificity, cancer vaccines are growing in popularity as potent therapeutic options in melanoma, kidney and ovarian cancer, to mention a few.
In order to successfully design a cancer vaccine, there is a strong need to identify reliable targets, or neoantigens, and for the neoantigens to be recognized by the T-cell receptor (TCR) on T-lymphocytes. My research focuses on integrating bioinformatics, immunological and genetic approaches to identify neoantigens and their corresponding TCRs in neoplastic tissues order to translate them into clinically usable cancer vaccines.
Alissa R. Verone-Boyle, Suzanne Shoemaker, Kristopher Attwood, Carl D. Morrison, Andrew J. Makowski, Sebastiano Battaglia, Pamela A. Hershberger. Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo (Oncotarget, 2015 Dec 8, [Epub ahead of print])
Doig CL, Battaglia S, Khanim FL, Bunce CM, Campbell MJ. Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells (J Steroid Biochem Mol Biol. 2015 Sep 28)
Long, Mark; van den Berg, Patrick; Russell, James; Singh, Prashant*; Battaglia, Sebastiano*; Campbell, Moray* (* - joint last authors). Integrative genomic analysis in K562 chronic myelogenous leukemia cells reveals that proximal NCOR1 binding positively regulates genes that govern erythroid differentiation and Imatinib sensitivity. (Nucleic Acids Res. 2015 Sep 3; 43(15): 7330–7348)
Battaglia S, Thorne J, Khanim, F, Gommersall LM, Coulter HSC, Rhaka S, Giddings, I. Cooper C, McCabe, CJ, Bunce CM, & Campbell MJ (2008). Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion - Carcinogenesis. 2010 Sep;31(9):1650-60
Battaglia, S., O. Maguire, and M.J. Campbell Transcription factor co-repressors in cancer biology; roles and targeting - Int J Cancer. 2010 Jun 1;126(11):2511